Compound A Tablet Formulation Without Blooming Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione (Compound A) lack advantageous physical and pharmaceutical properties, such as stability, bioavailability, and ease of administration, which are crucial for treating various chronic inflammatory conditions.
Innovation Solution
Development of pharmaceutical dosage forms of Compound A, including specific compositions of core formulations and coatings that exclude lower molecular weight excipients causing blooming effects, and utilize excipients like polydextrose, hypromellose, talc, and coloring agents to enhance stability and ease of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional pharmaceutical excipients are used in formulations of Compound A, then the formulation can be manufactured with standard processes, but the formulation exhibits blooming effects and reduced stability
Solution Approach 1:
The patent removes lower molecular weight excipients (specifically those with molecular weight less than 500 Da) from the formulation to eliminate the blooming effect. This extraction of harmful components resolves the contradiction by eliminating the source of the blooming phenomenon while maintaining formulation stability through the use of higher molecular weight excipients such as polydextrose, hypromellose, and talc.
2Reliability
If standard dosage forms are used for Compound A, then ease of manufacture is maintained, but bioavailability and stability are insufficient for effective treatment
Solution Approach 1:
The patent changes the molecular weight parameter of the excipients used in the formulation, specifically selecting excipients with molecular weights greater than 500 Da. This parameter change improves bioavailability and stability by preventing blooming effects, while the selected excipients (polydextrose, hypromellose, talc) remain compatible with standard manufacturing processes, thus maintaining ease of manufacture.
3Ease of manufacture
If lower molecular weight excipients are included in the formulation, then the formulation can be produced with simpler ingredients, but blooming effects occur on the tablet surface
Solution Approach 1:
The patent converts the potential harm of using simple, low molecular weight excipients into a benefit by deliberately selecting higher molecular weight excipients that prevent blooming. The excipients polydextrose, hypromellose, and talc provide both manufacturing simplicity and surface stability, transforming the excipient selection criteria into a solution that eliminates blooming while maintaining ease of manufacture.
4Manufacturing precision
If existing formulation compositions are used for Compound A, then development time is reduced, but the dosage forms lack advantageous physical and pharmaceutical properties
Solution Approach 1:
The patent applies preliminary action by pre-selecting and characterizing specific excipients (polydextrose, hypromellose, talc, and coloring agents) that are known to prevent blooming effects. This preliminary selection of optimized excipient combinations allows for faster formulation development while achieving superior dosage form quality, as the blooming prevention mechanism is built into the excipient selection rather than requiring extensive trial and error.
Data Source
AI summary
Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein. Also provided are methods of treating, managing, or preventing various diseases or disorders.